Introduction of metabolic pathways
1. Biological significance of metabolic pathways
Metabolic pathways are like precision production lines within cells, playing a crucial role in life activities. In the field of energy metabolism, take cellular respiration as an example. Glycolysis, the citric acid cycle, and oxidative phosphorylation work together in an orderly manner to gradually oxidize glucose, releasing the chemical energy stored within it and converting it into ——ATP, which can be directly utilized by the cell. This process provides a continuous supply of energy for various cellular activities, such as material transport and muscle contraction.
In terms of signal transmission, metabolic pathways serve as the bridge for communication between cells. When cells receive external signals, they activate specific metabolic pathways through a series of complex signaling pathways, thereby regulating physiological processes such as cell growth, differentiation, and apoptosis. These pathways interweave to form a complex yet orderly network, ensuring that cells can respond accurately to changes in both internal and external environments, maintaining normal life activities.
2. The role of metabolic pathways in disease
Metabolomics serves as a robust methodological framework for elucidating the intricate interactions between genetic determinants and environmental influences by dissecting metabolic pathways. Genes inherently define an organism's baseline metabolic capabilities and establish the architectural framework of its metabolic pathways. In contrast, environmental factors such as diet, pharmaceuticals, and pollutants exert significant impacts at the levels of gene expression and metabolism. Metabolomics enables the concurrent monitoring of shifts in metabolite profiles resulting from both genetic variations and environmental perturbations.
Genetic mutations can incite alterations in the functionality of metabolic enzymes, thereby disrupting the normal metabolic processes—disruptions that metabolomics is adept at identifying. Concurrently, environmental factors may also perturb these pathways, resulting in metabolite alterations. By examining the metabolomic profiles of organisms exposed to a range of environmental conditions across diverse genetic backgrounds, and integrating a comprehensive understanding of metabolic pathways, researchers can elucidate the synergistic role of genes and the environment in modulating metabolic processes.
In the study of hereditary diseases, specific gene mutations have been shown to increase individual sensitivity to particular environmental agents. Metabolomics analysis of alterations in metabolic pathways offers clarity on the interaction patterns between genetic and environmental factors pivotal to disease onset and progression. This approach unveils novel avenues for disease prevention and therapeutic strategies, emphasizing the intricate and dynamic relationship between an organism's genetic makeup and its environmental context.
(1) Immune Cell Metabolism and Inflammation
Immune cells adopt distinct metabolic programs:
M1 macrophages rely on aerobic glycolysis for proinflammatory responses, while M2 macrophages use oxidative phosphorylation (OXPHOS) and fatty acid oxidation (FAO) for anti-inflammatory functions.
Neutrophils depend on glycolysis for ATP and NADPH production, which are essential for reactive oxygen species (ROS) generation and neutrophil extracellular trap (NET) formation. Dysregulation of these pathways can lead to immunodeficiency or excessive inflammation.
(2) Metabolic Flexibility and Disease
Cells with constrained metabolic programs (e.g., neurons) depend on flexible cells (e.g., hepatocytes) for nutrient supply. Loss of metabolic flexibility in muscle contributes to metabolic syndrome. T-cells require aerobic glycolysis for proliferation during immune responses, and diabetes impairs this process, weakening immunity.
(3) Cancer and Metabolic Reprogramming
Cancer cells exhibit altered metabolism, such as the Warburg effect (aerobic glycolysis), to support rapid proliferation. Metabolic outliers like G6Pase deficiency in glycogen storage disease type 1a mimic oncogenic metabolic states, increasing hepatocellular carcinoma risk
Energy metabolism in autoimmune diseases.
3. The value of metabolic pathways in drug development
Metabolic pathways provide rich targets and clear directions for drug development. When a specific disease is identified as associated with an abnormality in a particular metabolic pathway, key enzymes and transport proteins on that pathway may become potential drug targets. For example, targeting the abnormally active metabolic pathways in cancer cells, developing drugs that specifically inhibit the activity of related enzymes can block the energy supply and biosynthesis pathways of cancer cells, thereby inhibiting tumor growth.
By studying metabolic pathways, we can also understand the mechanisms and metabolic processes of drugs in the body, which helps optimize drug design and improve therapeutic efficacy and safety. At the same time, drug development strategies based on metabolic pathways can more accurately target disease mechanisms, leading to the creation of more targeted personalized drugs. This provides patients with more effective treatment options and promotes a shift from traditional empirical approaches to mechanism-based precision research in drug development.
(1) Target Identification Through Metabolomics
Metabolomics provides a systems-level view of metabolic dysregulation in diseases, enabling the identification of key enzymes or transport proteins as potential drug targets. For example, analyzing altered metabolites in cancer cells has led to the development of inhibitors targeting glycolytic enzymes (e.g., GLUTs, HK2) and pathways like PI3K/Akt/mTOR. Similarly, metabolomics-driven approaches like dose-response studies and stable isotope tracing help pinpoint enzymes whose inhibition reverses metabolic abnormalities, such as restoring amino acid metabolism in diabetes.
(2) Cancer Metabolism as a Prime Target
Cancer cells exhibit distinct metabolic reprogramming (e.g., the Warburg effect), making pathways like glycolysis, fatty acid synthesis, and the TCA cycle attractive targets. Drugs such as FASN inhibitors and glycolytic inhibitors (e.g., 2-DG) are under clinical evaluation to disrupt energy production and biosynthesis in tumors. Additionally, synthetic lethal strategies exploit cancer-specific metabolic dependencies, such as targeting PTDSS1 in tumors with ethanolamine pathway deletions.
(3) Personalized Medicine and Metabolic Subtyping
Metabolic subtyping identifies patient-specific metabolic vulnerabilities, enabling tailored therapies. For instance, pancreatic cancer subtypes with high glycolytic activity may benefit from glycolysis inhibitors, while cholesterogenic subtypes could respond to lipid-targeted therapies. Metabolomics also aids in predicting drug responses and toxicity, supporting "P4 medicine" (predictive, preventive, personalized, participatory). However, challenges like high costs and regulatory hurdles hinder widespread adoption.
(4) Combination Therapies and Synergy
Metabolic inhibitors are often combined with chemotherapy or immunotherapy to enhance efficacy. For example, mTOR inhibitors improve responses to chemo/immunotherapy by modulating tumor-immune cell interactions. However, metabolic heterogeneity in tumors and cross-talk between pathways complicate monotherapy approaches, necessitating combination strategies.
(5) Emerging Tools for Target Discovery
Advanced techniques like single-cell metabolomics, mass spectrometry imaging, and AI-driven analysis are accelerating target identification. These methods integrate metabolic data with structural biology to predict off-target effects (e.g., CD15-3 antibiotic targets) and validate candidate enzymes. Multiomics approaches further refine mechanistic insights by linking metabolite changes to protein interactions.
Dose–response metabolomics target identification flowchart.
The technical correlation between metabolomics and metabolic pathways
1. The analysis principle of metabolomics
Metabolomics focuses on all metabolic products within an organism, analyzing changes in these metabolites to infer key metabolic pathways. Metabolites within organisms are in dynamic equilibrium; when subjected to internal genetic changes or external environmental stimuli, the types and quantities of metabolites can alter. Metabolomics employs advanced analytical techniques such as nuclear magnetic resonance (NMR), mass spectrometry (MS), and liquid chromatography-mass spectrometry to conduct comprehensive qualitative and quantitative analyses of metabolites in biological samples (such as plasma, urine, etc.). By comparing the differences in metabolites under various physiological or pathological conditions, it identifies metabolites with significant changes. These differential metabolites often represent critical nodes in specific metabolic pathways, allowing for the inference of which pathways are activated or inhibited under corresponding conditions. This approach enables the reverse inference from changes in metabolites to key metabolic pathways, providing clues for a deeper understanding of biological activities and disease mechanisms.
2. Revealing the mechanism of gene-environment interaction
Metabolomics offers a formidable approach for delineating the intricate mechanisms underpinning the interplay between genetic factors and environmental influences via the analysis of metabolic pathways. Genes establish the foundational metabolic capacity of an organism and shape the overarching structure of these pathways. Conversely, environmental factors, including diet, pharmaceuticals, and pollutants, exert effects at both gene expression and metabolic levels. Metabolomics facilitates the concurrent monitoring of metabolite changes attributed to both genetic and environmental influences.
Genetic mutations can precipitate alterations in metabolic enzyme activity, subsequently disrupting the standard functioning of metabolic pathways—abnormalities that metabolomics can adeptly detect. Simultaneously, environmental factors may disrupt these pathways, engendering alterations in metabolite profiles. By scrutinizing the metabolomes of organisms subjected to diverse environmental conditions across varying genetic landscapes—and integrating knowledge of metabolic pathways—researchers can elucidate the cooperative dynamics between genes and the environment in mediating metabolic processes.
In the realm of hereditary diseases, certain gene mutations have been identified that heighten individual susceptibility to specific environmental agents. Employing metabolomics to analyze changes in metabolic pathways enables the clarification of interaction paradigms between genetic and environmental factors during disease onset and progression. This approach furnishes novel insights into potential strategies for disease prevention and therapeutic intervention, highlighting the nuanced relationship between an organism's genetic blueprint and its environmental context.Development of metabolomics technology
Metabolomics technology has made significant progress since its inception. In the mid-1990s, the concept of metabolomics was introduced, initially relying heavily on nuclear magnetic resonance techniques. Although these methods could qualitatively analyze metabolites, their sensitivity was limited. With technological advancements, mass spectrometry gradually became an essential tool in metabolomics research. Its high sensitivity and resolution enable more accurate identification and quantification of metabolites. The emergence of chromatography-mass spectrometry further enhanced the separation and detection capabilities of metabolites, achieving high-throughput analysis of multiple metabolites in complex biological samples. In recent years, metabolomics technology has continued to innovate, with improvements in the resolution and scanning speed of high-resolution mass spectrometers, as well as a wider range of sample types that can be analyzed, including plasma, serum, urine, saliva, and extracts from cells and tissues. Today, metabolomics technology is widely applied in clinical medicine, basic medicine, pharmacy, zoology and botany, microbiology, environmental science, and other fields, providing robust technical support for research across various disciplines and advancing towards greater precision, comprehensiveness, and efficiency.
Services You May Be Interested In:
Additional Resources:
Case for metabolic pathway analysis
1. Gut Microbiota Dysbiosis in Parkinson's Disease: Insights from Metagenomic Analysis
Study Overview
In a pivotal investigation documented in Parkinsonism & Related Disorders (Parashar & Udayabanu, 2017), a comprehensive metagenomic analysis was executed on fecal samples derived from patients diagnosed with Parkinson's disease (PD) (n = 490) and healthy control subjects (n = 234). This study revealed pronounced dysbiosis within the gut microbiota of individuals with PD. Notably, there was a substantial elevation in the abundance of 55 microbial taxa, including but not limited to Enterobacteriaceae, coupled with a marked reduction in 29 taxa, epitomized by Prevotellaceae. These microbial alterations were systematically correlated with the manifestation of both motor and non-motor symptoms associated with PD, such as gastrointestinal disturbances and cognitive impairments.
Mechanistic Insights
Employing the KEGG pathway database, the research delineated significant perturbations in the biosynthesis pathways of short-chain fatty acids (SCFA) and tryptophan metabolism within the PD-associated microbiota. A critical observation was the diminished production of neuroprotective metabolites, such as butyrate, alongside an augmented synthesis of pro-inflammatory compounds, notably lipopolysaccharides. These metabolic aberrations are hypothesized to exacerbate the aggregation of α-synuclein and foster neuroinflammation, mediated by the gut-brain axis, thus contributing to the pathogenesis of Parkinson's disease.
Significance
This study constitutes the first systematic evidence underscoring the connection between gut microbial dysbiosis and metabolic pathway disruptions in Parkinson's disease, thereby establishing a conceptual framework for potential microbiota-targeted therapeutic strategies.
2. Metabolic Pathway Analysis for Biomarker Discovery in Parkinson's Disease
Case Application
A 2020 study in Gut (DOI:10.1136/gutjnl-2019-319723) employed metabolic pathway analysis to identify candidate biomarkers in PD. The investigation revealed hyperactivity in the phenylalanine/tyrosine metabolic pathway, leading to diminished synthesis of dopamine precursors, and upregulation of glutamate metabolism, which may contribute to neuroexcitotoxicity. Key enzymes (e.g., tyrosine hydroxylase) and metabolites (e.g., p-cresol) within these pathways were validated as potential biomarkers for PD.
Clinical Implications
Early Diagnosis: Fecal metagenomic profiling of pathway activity (e.g., tryptophan-to-serotonin conversion rates) enables identification of high-risk individuals prior to the onset of motor symptoms.
Disease Monitoring: Aberrant pathway activity correlates with disease severity, as measured by the Unified Parkinson's Disease Rating Scale (UPDRS). For instance, increased Lactobacillus abundance inversely predicts levodopa responsiveness.
Targeted Therapies: Interventions modulating microbial metabolism, such as probiotic supplementation with butyrate-producing bacterial strains, have demonstrated efficacy in improving motor function in PD patients during Phase II clinical trials.
The core advantage of metabolomics analysis
Metabolomics analysis present a multitude of notable advantages, significantly advancing both research methodologies and clinical applications. Their high-throughput detection capabilities allow for the exhaustive analysis of hundreds to thousands of metabolites in biological samples within a single assay. This capability ensures the rapid acquisition of comprehensive metabolic data, markedly enhancing research efficiency and circumventing the extensive time and resource demands associated with individual metabolite testing.
A key feature of metabolomics services is their precise quantification capability. By employing sophisticated techniques such as mass spectrometry, these services can accurately quantify metabolite concentrations, including those occurring at trace levels. Such precision lays a robust and dependable groundwork for subsequent data analyses and conclusion formulation.
Furthermore, metabolomics services are characterized by their broad applicability, adeptly analyzing a wide array of biological specimens including blood, urine, and various tissue and cell extracts. They effectively encapsulate alterations in an organism's metabolic state, whether due to disease-induced metabolic disorders or drug-induced metabolic changes. This comprehensive representation of metabolic dynamics provides invaluable insights into biological processes and disease mechanisms for researchers and clinicians alike.
Metabolomics Analysis Methods of Metabolic Pathways
1. Selection and Comparison of Data Acquisition Techniques
Metabolomics research is predicated on high-precision metabolite detection methodologies. Currently, the primary techniques include:
Nuclear Magnetic Resonance (NMR): NMR's strength lies in its ability to analyze biological fluids (e.g., blood, urine) without sample derivatization, maintaining sample integrity. It is especially suitable for dynamic metabolic tracking. However, its sensitivity is relatively low (detection limit around the μM range), and high maintenance costs of equipment limit its application in low-abundance metabolite research.
Gas Chromatography-Mass Spectrometry (GC-MS): Known for its high resolution and standardized database support, GC-MS is ideal for volatile metabolites like organic acids and sugars. However, it requires derivatization and cannot detect large molecular lipids and thermally unstable substances.
Liquid Chromatography-Mass Spectrometry (LC-MS): Offering broad coverage, LC-MS effectively analyzes non-volatile metabolites, such as amino acids and lipids. Innovations such as Met4DX in four-dimensional metabolomics significantly enhance stereochemical isomer differentiation. Nevertheless, its limited database coverage necessitates a reliance on untargeted analysis strategies.
Capillary Electrophoresis-Mass Spectrometry (CE-MS): CE-MS is suitable for polar metabolite analysis with high resolution, identifying over a thousand metabolites. Its disadvantage lies in rigorous pre-treatment requirements and operational instability.
2. Statistical Analysis and Biomarker Discovery
Metabolomics data analysis integrates multivariate statistical methods to reduce dimensionality and identify key metabolites:
Principal Component Analysis (PCA): As an unsupervised dimensionality-reduction method, PCA provides initial data visualization and outlier detection but is unable to distinguish intergroup differences.
Partial Least Squares Discriminant Analysis (PLS-DA): A supervised model that maximizes between-group differences to identify potential biomarkers, although susceptible to noise interference. The orthogonal variant, OPLS-DA, improves model explanatory power by removing orthogonal variation, making it the preferred choice for disease biomarker research.
3. Application and Evaluation of Pathway Enrichment Tools
Metabolic pathway analysis relies on bioinformatics tools, with MetaboAnalyst 5.0 being the most widely used online platform:
Functional Features: It supports three types of input (metabolite names, HMDB ID, and KEGG ID) and automates ID conversion and pathway mapping. It offers both hypergeometric and Fisher's exact tests, combined with topological analysis (degree centrality, betweenness centrality) to evaluate pathway significance. Bubble plots provide an intuitive display of significance (log§) and pathway impact values.
Advantages and Limitations: MetaboAnalyst simplifies multi-database ID conversion, supports cross-species pathway mapping (e.g., human, mouse), and generates interactive visualization reports with ease. However, its species coverage is limited (lacking in rare model organisms), automatic conversions may overlook some metabolites, and results often bias toward drug metabolism-related pathways.
Alternative Tools: Shanghai Institute of Organic Chemistry's Met4DX enhances metabolite identification accuracy with four-dimensional mass spectrometry technology; the Ref-M strategy utilizes reference materials to eliminate batch effects, improving early lung adenocarcinoma biomarker screening accuracy by 20%.
4. Future Directions
Metabolomics is advancing toward multi-omics integration and high-precision analysis:
Fluxomics: Using 13C labeling to track metabolic fluxes provides insights into the dynamic balance between tumor glycolysis and the TCA cycle.
Spatial Metabolomics: Based on MALDI mass spectrometry imaging, this technique maps the spatial distribution of metabolites within tissues, offering new perspectives for cancer heterogeneity research.
Conclusion
The choice of metabolic pathway analysis technology should align with research objectives: targeted studies favor GC-MS/LC-MS, while untargeted explorations benefit from integration with deep learning and four-dimensional mass spectrometry. In tool selection, MetaboAnalyst suffices for rapid pathway enrichment, yet complex disease studies necessitate multi-omics data integration and novel correction strategies. With ongoing technological innovations, metabolomics promises substantial contributions to precision medicine and environmental health domains.
References
- DeBerardinis RJ, Thompson CB. Cellular metabolism and disease: what do metabolic outliers teach us? Cell. 2012 Mar 16;148(6):1132-44. doi: 10.1016/j.cell.2012.02.032. PMID: 22424225; PMCID: PMC3337773.
- Stojkov D, Gigon L, Peng S, Lukowski R, Ruth P, Karaulov A, Rizvanov A, Barlev NA, Yousefi S, Simon HU. Physiological and Pathophysiological Roles of Metabolic Pathways for NET Formation and Other Neutrophil Functions. Front Immunol. 2022 Feb 9;13:826515. DOI: 10.3389/fimmu.2022.826515. PMID: 35251008; PMCID: PMC8889909.
- Liu, H., Wang, S., Wang, J. et al. Energy metabolism in health and diseases. Sig Transduct Target Ther 10, 69 (2025). https://doi.org/10.1038/s41392-025-02141-x
- You, M., Xie, Z., Zhang, N. et al. Signaling pathways in cancer metabolism: mechanisms and therapeutic targets. Sig Transduct Target Ther 8, 196 (2023). https://doi.org/10.1038/s41392-023-01442-3
- Parashar A, Udayabanu M. Gut microbiota: Implications in Parkinson's disease. Parkinsonism Relat Disord. 2017 May;38:1-7. DOI: 10.1016/j.parkreldis.2017.02.002. 2017.02.002. Epub 2017 Feb 7. PMID: 28202372; PMCID: PMC7108450.
- Mulak A, Bonaz B. Brain-gut-microbiota axis in Parkinson's disease. World J Gastroenterol. 2015 Oct 7;21(37):10609-20. doi: 10.3748/wjg.v21.i37.10609. PMID: 26457021; PMCID: PMC4588083.
- Pan S, Yin L, Liu J, Tong J, Wang Z, Zhao J, Liu X, Chen Y, Miao J, Zhou Y, Zeng S, Xu T. Metabolomics-driven approaches for identifying therapeutic targets in drug discovery. MedComm (2020). 2024 Nov 11;5(11):e792. doi: 10.1002/mco2.792. PMID: 39534557; PMCID: PMC11555024.
